IIT Bombay Discovers a Safer Way to Lower LDL Cholesterol

Researchers from IIT Bombay have discovered a promising mechanism that could revolutionize cholesterol treatment. Consequently, this breakthrough offers a safer way to lower blood lipids without triggering fat accumulation in the liver.

A Novel Approach to Cholesterol Treatment

Historically, conventional lipid-lowering therapies targeted enzymes, receptors, or genes. However, this new study targets the physical movement of lipid droplets within liver cells. Specifically, researchers from IIT Bombay, IISER Pune, and IISER Kolkata collaborated to interrupt this cellular transport. Because of this targeted approach, the liver does not release harmful very-density lipoproteins (VLDL) into the bloodstream. Furthermore, this method prevents lipids from building up in the liver, which is a major safety advantage.

How the KTDP Peptide Prevents Lipid Transport

To achieve this, Professor Roop Mallik’s laboratory focused on a motor protein called kinesin-1. Previously, his team showed that kinesin-1 drives lipid droplets toward the cell edge for VLDL assembly. Therefore, the researchers engineered a short peptide named KTDP, derived from the tail region of kinesin-1. Additionally, this peptide selectively blocks the motor protein from attaching to lipid droplets. Interestingly, computer simulations at IISER Kolkata revealed that KTDP forms a highly stable bond with the unique monolayer surface of lipid droplets. Consequently, standard bilayer cell membranes remain unaffected by this peptide, ensuring high specificity.

Preclinical Success and Future Outlook

Initially, the team successfully tested the KTDP peptide in cultured rat liver cells. Following this success, they utilized transparent zebrafish larvae to directly visualize lipid transport. Remarkably, the treatment reduced plasma triglycerides and cholesterol by approximately 50 percent. Moreover, the animal models showed no developmental abnormalities or liver toxicity. Although this work is currently in the preclinical stage, it points to a very promising therapeutic direction. Eventually, future studies will evaluate long-term safety and optimize peptide delivery in mammals.

Frequently Asked Questions

Q1: What is KTDP and how does it lower cholesterol?

KTDP is a short peptide derived from the kinesin-1 motor protein. Specifically, it blocks the transport of lipid droplets, preventing them from being assembled into harmful VLDL and released into the bloodstream.

Q2: Does blocking lipid export cause fat buildup in the liver?

No, the study demonstrated that disrupting this specific mechanism does not cause lipid accumulation in the liver. Instead, this safety profile provides a major advantage over traditional therapies.

Q3: Is this cholesterol treatment available for humans?

Currently, the research is in the preclinical stage. Consequently, researchers must conduct future studies to evaluate its long-term safety and efficacy in mammals before human trials can begin.

References

1. IIT Bombay study identifies safer pathway to tackle cholesterol, fatty liver – ETHealthworld
2. Selective targeting of kinesin on lipid droplets in the liver reduces plasma lipids – PNAS
3. IIT Bombay scientists find a new way to lower LDL cholesterol – The Indian Express

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.